Point of Care Infectious Disease Testing Market
Report ID: SQMIG35A3919
Report ID: SQMIG35A3919
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A3919 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
128
|Figures:
77
Global Point Of Care Infectious Disease Testing Market size was valued at USD 12.8 Billion in 2024 and is poised to grow from USD 13.59 Billion in 2025 to USD 22.0 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).
A major driver of the Global Point of Care Infectious Disease Testing Market is the growing need for rapid diagnosis at the patient’s location. Traditional lab tests involve transportation of specimens to the lab, followed by time consuming processing before clinicians can make decisions about treatments. The continuing burden of infectious diseases like influenza, COVID-19, RSV, TB and STDs on the public’s health has caused providers to turn increasingly toward point-of-care test (POCT) methods for getting quick results. Obtaining quicker diagnoses leads to getting started on treatment sooner, reducing the spread of communicable disease from one person to another, improving the chance that patients will get better, and lowering the cost of caring for patients. As a result, hospitals, clinics, pharmacies and community-based health centers are increasingly expanding their use of POCTs for infectious disease testing.
A key factor influencing market growth is the continuous advancement of molecular diagnostic technologies. Portable PCR devices, multiplex testing technologies (that enable multiple tests on one sample), microfluidics and digital connectivity have delivered substantial improvements in the accuracy and reliability of point-of-care testing. The use of these technological advances has allowed for the rapid detection of multiple pathogens from a single specimen in minutes while providing laboratory level accuracy. As point-of-care testing continues to become more accurate, easier to use and more widely available, clinician confidence in point-of-care testing is likely to continue to rise and regulatory authorizations will accelerate. Consequently, there will be more widespread use of point-of-care testing in various health care settings paving the way for the expansion of the point-of-care testing market and supporting physician movement toward personal and decentralized management of infectious diseases.
How is AI Enhancing Point‑of‑Care Infectious Disease Testing Accuracy?
Infection testing conducted at the point of care is being transformed by artificial intelligence. This is being accomplished through the use of AI to provide automated interpretation of test results, optimise assay designs, and integrate testing data with clinical decision-making support (CDSS). The use of machine learning algorithms enables the analysis of either optical or electrical signals (generated by compact cartridges) to accurately distinguish between true pathogen signatures and background noise, with greater reproducibility than human reading of the same signals. Real-time algorithms can modify their test threshold, based upon the patient's individual clinical history and the current epidemiological characteristics of the population As the U.S. market for point‑of‑care infectious disease testing expands, AI‑enhanced platforms are becoming a key driver of adoption and confidence.
In July 2025, Seegene launched STAgora™, an AI-powered infectious disease analytics platform that integrates syndromic PCR testing with real-time data analysis. The system provides predictive outbreak insights, supports faster clinical decision-making, and enhances point-of-care infectious disease management by transforming diagnostic results into actionable intelligence for healthcare providers and public health authorities.
Market snapshot - (2026-2033)
Global Market Size
USD 12.8 Billion
Largest Segment
Molecular Diagnostics Tests
Fastest Growth
Immunoassay-Based Tests
Growth Rate
6.2% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global point of care infectious disease testing market is segmented by product type, disease type, technology, end user and region. Based on product type, the market is segmented into rapid antigen tests, molecular diagnostics tests, immunoassay-based tests and others. Based on disease type, the market is segmented into respiratory infections, sexually transmitted infections (STIs), healthcare-associated infections (HAIs), tropical & vector-borne diseases, gastrointestinal infections, hepatitis infections and others. Based on technology, the market is segmented into lateral flow assays, polymerase chain reaction (PCR), isothermal nucleic acid amplification, microfluidics-based testing, immunoassay technologies and others. Based on end user, the market is segmented into hospitals & emergency departments, clinics & physician offices, diagnostic laboratories, ambulatory care centers, home care settings and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Rapid antigen tests segment dominates because it delivers immediate results with minimal equipment, fitting the urgent decision‑making workflow of clinicians at the bedside. The simplicity of lateral flow design eliminates the need for specialized laboratories, enabling widespread distribution in varied care settings. This ease of use combined with lower cost per assay drives high adoption rates and entrenches its position as the primary point‑of‑care solution for infectious disease detection.
However, molecular diagnostics tests segment witnesses the strongest growth momentum as nucleic acid amplification technologies evolve. Innovations that embed cartridge‑based PCR into handheld devices cut turnaround time while preserving high sensitivity. Growing clinical confidence in molecular accuracy drives broader adoption, making this area a catalyst for market expansion and diagnostic capability.
Isothermal nucleic acid amplification segment dominates because it delivers rapid amplification without thermal cycling, allowing bedside testing with minimal equipment. Integrating the simple chemistry to disposable cartridges reduces user work and contamination risk. Clinicians also find the unique combination of the ability to rapidly analyze samples while maintaining high sensitivity gives versatility to the clinical application area because of the ability to detect multiple targets at one time. These attributes collectively drive widespread adoption, establishing it as the leading technology for point‑of‑care infectious disease diagnostics.
Meanwhile, microfluidics-based testing segment experiences rapid expansion as engineers create integrated chips that automate sample preparation, amplification and readout in a portable device. The reduction of reagent volumes and data transmission suit care settings. Growing investment in chip design and regulatory pathways speeds market entry, making microfluidics a pivotal driver of future point‑of‑care growth.
To get detailed segments analysis, Request a Free Sample Report
North America retains a commanding position in the point of care infectious disease testing market thanks to a mature healthcare infrastructure, extensive network of research institutions, and strong commitment to innovation. Rapid uptake of high-tech diagnostic platforms by hospital, clinic and community health settings will be facilitated by an high awareness of those technologies by clinicians and demand for immediate results by patients. Strong reimbursement models and regulatory pathways will facilitate product entry and market growth. Collaborative ecosystems of manufacturers, technology developers and academic institutions will assist in continuing to develop multiplex and molecular solutions in this area, thus maintaining the region's status as a leader and maintaining the growth of the market. In addition, the presence of global corporations with established distribution channels increases reach in the market, and strong investment in digital health integration will improve connectivity of data among care sites.
Point of care infectious disease testing market in the United States is propelled by an extensive network of hospitals and ambulatory clinics that prioritize rapid diagnostics to streamline patient management. Effective partnerships between biotech companies and academic hospitals will speed up the introduction of new molecular assays. Point of care solutions will be encouraged through reimbursement models and have a greater chance of acceptance in both rural and urban areas. The public has access to innovative assays through an ecosystem that allows for rapid regulatory clearance.
Point of care infectious disease testing market in Canada benefits from a publicly funded health system that emphasizes equitable access to timely diagnostic services. Health authorities use point of care technologies in their primary health care clinics and remote community clinics across the province. National research programs with laboratories are working together to support the development and validation of new assay tests; meanwhile, the government’s procurement policy is based on finding the most cost effective method to offer these tests and support their widespread usage throughout the country.
Europe experiences rapid expansion of the point of care infectious disease testing market driven by strong public health initiatives, integration of digital health frameworks, and a collaborative regulatory environment. To enhance patient outcomes and respond to outbreaks, health authorities collectively aim to reduce the time needed from performing tests to obtaining results by implementing more decentralized testing at hospitals and community centers. The growth of innovative multidimensional and rapid molecular testing technologies continues to be driven by a wide range of diagnostic manufacturers operating in this space and strong partnerships between the diagnostics manufacturers and their local research institutions. Moreover, cross‑border cooperation and harmonized standards simplify market entry and encourage broader distribution of advanced point of care solutions throughout the European market. In addition, reimbursement policies that reward timely diagnosis encourage healthcare providers to integrate point of care platforms into routine practice, while patient awareness of rapid testing benefits drives demand across primary care and travel health clinics.
Point of care infectious disease testing market in Germany is anchored by a strong industrial base and a high degree of collaboration between hospitals, research universities and diagnostic firms. The German healthcare system prioritizes efficiency and early detection, leading to widespread implementation of rapid testing in acute care and outpatient settings. Federal funding programs support the development of next‑generation molecular assays, while reimbursement structures favor cost‑effective point of care solutions, reinforcing Germany’s leading market position.
Point of care infectious disease testing market in the United Kingdom is accelerating through strategic initiatives that emphasize rapid diagnostic access in both metropolitan hospitals and remote community clinics. National health agencies promote integration of point of care platforms to alleviate pressure on laboratory services and improve patient flow. When biotech innovators collaborate strongly with NHS Trusts, they can expedite validation of novel assays. Policy frameworks that incentivise early detection will support the rapid expansion of testing capabilities throughout the UK.
Point of care infectious disease testing market in France is emerging as health authorities seek to broaden access to rapid diagnostics within primary care networks and emergency departments. The collaboration between French biotechnology firms and university research labs is focused on adapting multiplex technology to meet local clinical requirements. Clinicians will have incentives to adopt point of care technologies through reimbursement policy changes showing the value of delivering timely results; additionally, there are public health efforts to educate the community on the advantages of early detection of infectious diseases.
Asia Pacific is strengthening its position in the point of care infectious disease testing market through concerted investments in healthcare infrastructure, a surge in digital health adoption, and proactive government strategies aimed at enhancing pandemic preparedness. The market dynamics in this area are so diverse that they allow for local manufacturers to create cost-effective, portable diagnostic devices that are appropriate for many different types of clinical settings. By integrating mobile health platforms with point of care testing, real-time data sharing supports timely decision-making at both urban hospitals and remote clinics. In addition, through collaboration between public and private partners, the technology can be transferred and clinically validated quickly; thus establishing a solid ecosystem for the broader acceptance of rapid infectious disease testing throughout the Asia Pacific region. Through educational programs to train clinicians on their workflows with point of care testing, these technologies will then become more routine in their use. Lastly, regional trade agreements have simplified the ability to distribute approved testing kits to all of the diverse economies within the region, allowing for a greater market penetration overall.
Point of care infectious disease testing market in Japan is propelled by a technologically sophisticated health system that embraces automation and high‑throughput diagnostic solutions. The government is focusing on rapidly testing in order to meet the health needs of an aging population and to help prevent the transmission of infectious diseases in large, tightly packed urban areas. The collaboration of Japanese medical equipment manufacturers and research facilities has been extremely beneficial for the development of customized solutions that are specific to each region's pathogens, while also providing reimbursement incentives that encourage widespread adoption by hospitals and community clinics.
Point of care infectious disease testing market in South Korea benefits from a highly connected healthcare environment where digital integration supports seamless test ordering and result reporting. National public health initiatives support early identification interventions and rapid responses, encouraging hospitals as well as outpatient facilities to integrate point of care/POC devices into their normal work processes. The commercial feasibility of implementing POC testing throughout the country is also being improved by government reimbursement programs for rapid diagnosis of disease.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Demand For Point‑of‑Care Tests
Advancements In Molecular Diagnostic Technology
Stringent Regulatory Approval Processes
High Cost Of Testing Platforms
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape in the global point of care infectious disease testing market is shaped by intense rivalry among established diagnostics firms and emerging players, with market expansion driven by the need for rapid, accurate infectious disease results at the point of care. Companies are pursuing technology innovation, exemplified by the rollout of multiplex molecular platforms that deliver results in minutes, and strategic partnerships with health‑system networks to broaden distribution and accelerate adoption.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the market is propelled primarily by the rising demand for point‑of‑care tests that deliver immediate results, while a second strong driver is the rapid advancement of molecular diagnostic technologies that improve sensitivity and enable multiplexing at the bedside. The dominant segment continues to be rapid antigen tests, thanks to their simplicity and low cost, and North America leads the market thanks to its mature healthcare infrastructure and strong reimbursement support. However, progress is tempered by the restraint of stringent regulatory approval processes, which lengthen development timelines and increase costs, limiting faster adoption of newer platforms in clinical practice worldwide.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 12.8 Billion |
| Market size value in 2033 | USD 22.0 Billion |
| Growth Rate | 6.2% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Point of Care Infectious Disease Testing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Point of Care Infectious Disease Testing Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Point of Care Infectious Disease Testing Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Point of Care Infectious Disease Testing Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Point Of Care Infectious Disease Testing Market size was valued at USD 12.8 Billion in 2024 and is poised to grow from USD 13.59 Billion in 2025 to USD 22.0 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).
The competitive landscape is shaped by intense rivalry among established diagnostics firms and emerging players, with market expansion driven by the need for rapid, accurate infectious disease results at the point of care. Companies are pursuing technology innovation, exemplified by the rollout of multiplex molecular platforms that deliver results in minutes, and strategic partnerships with health‑system networks to broaden distribution and accelerate adoption. 'Abbott Laboratories', 'F. Hoffmann-La Roche Ltd', 'Danaher Corporation', 'bioMérieux SA', 'QIAGEN N.V.', 'Becton, Dickinson and Company', 'Siemens Healthineers AG', 'QuidelOrtho Corporation', 'Cepheid', 'Trinity Biotech plc', 'OraSure Technologies, Inc.', 'Chembio Diagnostics, Inc.', 'Sekisui Diagnostics, LLC', 'Meridian Bioscience, Inc.', 'Nova Biomedical Corporation', 'EKF Diagnostics Holdings plc', 'Visby Medical, Inc.', 'LumiraDx Limited', 'Binx Health, Inc.', 'SD Biosensor, Inc.'
The growing prevalence of infectious diseases in community and hospital settings drives demand for immediate diagnostic information, prompting clinicians to adopt point‑of‑care solutions that deliver results within minutes. Rapid identification enables timely treatment decisions, infection control measures, and reduced transmission risk, which collectively enhance patient outcomes and operational efficiency. Consequently, healthcare providers prioritize investments in portable testing devices that can be deployed at bedside, in clinics, or in remote locations, fueling market expansion across various healthcare systems worldwide and supporting public health initiatives.
Rapid Molecular Integration: Healthcare providers are increasingly adopting rapid molecular platforms that deliver accurate infectious disease results within minutes, enabling point‑of‑care decisions that were previously confined to central laboratories. This shift is driven by the need for immediate treatment initiation, reduced patient wait times, and the ability to manage outbreak hotspots directly in clinics, pharmacies, and community health centers. As clinicians recognize the clinical and operational benefits, demand for portable, user‑friendly devices that can be deployed across diverse care settings continues to accelerate.
Why does North America Dominate the Global Point of Care Infectious Disease Testing Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
